Status:
RECRUITING
Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
Catholic University of the Sacred Heart
Conditions:
Pancreas Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) complexity, where genetic, stromal, and immunological factors all interact with each other, is responsible for the overall poor response of PDAC to chemotherape...
Eligibility Criteria
Inclusion
- Patients referred to EUS with FNB for suspected pancreatic cancer unresectable or metastatic based on imaging findings
- Availability of biopsies obtained during EUS-FNB
- Histological diagnosis of pancreatic ductal adenocarcinoma of any stage
- Patients must be fit for chemotherapy administration
- They have to express their willingness to be followed up at our pancreatic high volume centers
- Age \>18 and \<80 years
- Able to sign informed consent
Exclusion
- Histological diagnoses other than pancreatic ductal adenocarcinoma
- Pregnancy or lactation
Key Trial Info
Start Date :
July 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 10 2026
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05248750
Start Date
July 22 2021
End Date
July 10 2026
Last Update
February 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Agostino Gemelli" Hospital, Catholic University of Sacred Heart
Rome, Lazio, Italy, 00168